Septolete Neo

Země: Arménie

Jazyk: angličtina

Zdroj: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Aktivní složka:

cetylpyridinium chloride (cetylpyridinium chloride monohydrate)

Dostupné s:

KRKA d.d.

INN (Mezinárodní Name):

cetylpyridinium chloride (cetylpyridinium chloride monohydrate)

Dávkování:

1,2mg

Léková forma:

lozenges with cherry flavour

Druh předpisu:

OTC

Charakteristika produktu

                                1.3.1
Cetylpyridinium chloride
SPC, Labeling and Package Leaflet
AM
SmPCPIL045437_1
06.12.2013 – Updated: 06.12.2013
Page 1 of 5
1.
NAME OF THE MEDICINAL PRODUCT
Septolete Neo Cherry lozenges 1.2 mg
Septolete Neo Apple lozenges 1.2 mg
Septolete Neo Lemon lozenges 1.2 mg
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each lozenge contains 1.2 mg cetylpyridinium chloride.
For excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Lozenges.
Septolete Neo Cherry: violet, round, slightly biconvex lozenges.
Septolete Neo Apple: green, round, slightly biconvex lozenges.
Septolete Neo Lemon: yellow, round, slightly biconvex lozenges.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Septolete Neo lozenges are recommended in infectious-inflammatory
diseases of the mouth
and throat:
- pharyngitis, laryngitis, beginning of angina,
- inflammation of the gums and oral mucous membrane (gingivitis,
stomatitis).
4.2.
POSOLOGY AND METHOD OF ADMINISTRATION
The recommended dosage for adults and children over 12 years of age is
up to 8 lozenges a
day. Dissolve 1 lozenge in the mouth every 2 to 3 hours.
For children over 4 years of age, up to 4 lozenges a day are
recommended while for children
from 10 to 12 years of age, up to 6 lozenges a day. Dissolve 1 lozenge
in the mouth every 3 to
4 hours.
The lozenges should not be taken immediately before or during meals.
4.3
CONTRAINDICATIONS
Hypersensitivity to cetylpyridinium chloride or to any of the
excipients.
Children under 4 years of age.
4.4
SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE
1.3.1
Cetylpyridinium chloride
SPC, Labeling and Package Leaflet
AM
SmPCPIL045437_1
06.12.2013 – Updated: 06.12.2013
Page 2 of 5
The lozenges should not be taken in open wounds in the mouth because
cetylpyridinium
chloride slows the healing of wounds.
In severe infections accompanied by high fever, headache and vomiting,
a physician should
be consulted, especially if the condition does not improve in three
days.
Diabetic patients should bear in mind that each lozenge contains
around 1 g of maltitol
                                
                                Přečtěte si celý dokument
                                
                            

Dokumenty v jiných jazycích

Informace pro uživatele Informace pro uživatele ruština 30-01-2014

Vyhledávejte upozornění související s tímto produktem

Zobrazit historii dokumentů